Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509067 · ClinicalTrials.gov registry record · Phase 2
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
A Phase 2 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00509067 is a Phase 2 study that has completed, run by Georgetown University. The registered enrollment target is 43 participants.
The verdict
NCT00509067, a Phase 2 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.
Interventions
- DRUG Placebo
- DRUG Galantamine
- DRUG CDP-choline
- DRUG risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509067
The ClinicalTrials.gov registry entry for NCT00509067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00509067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509067 about?
NCT00509067 is a clinical study titled "Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia". This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia.
What is the current status of trial NCT00509067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2007-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00509067?
The interventions under investigation include: Placebo (DRUG), Galantamine (DRUG), CDP-choline (DRUG), risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00509067?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.